Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen (AXGN) priced an underwritten public offering of 4,910,000 common shares at $42.50 per share on September 10, 2026.
The company expects gross proceeds of approximately $208.7 million, excluding any exercise of the underwriters’ 30-day option to purchase up to an additional 736,500 shares at the same public price, less underwriting discounts and commissions. The offering is expected to close on September 11, 2026, subject to customary conditions. Axogen plans to use substantially all net proceeds to fund the cash consideration and related fees for its previously announced BioCircuit Technologies acquisition, with any remaining funds, or all proceeds if the deal does not close, for general corporate purposes.
Axogen (AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the FDA-approved sutureless nerve repair device NerveTape™.
The cash consideration at closing is subject to customary adjustments, with $1.0 million withheld pending a post-closing purchase price adjustment. Closing is expected in the fourth quarter of 2026, contingent on standard conditions, including completion of a spin-out of BioCircuit’s electronics research and development business. NerveTape, described as the first FDA-approved device for sutureless peripheral nerve repair, is expected to broaden Axogen’s addressable market and benefit from its existing sales force, surgeon relationships and hospital contracting.
Axogen expects the deal to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year after closing while remaining free cash flow positive, and to be additive to 2027 revenue with accretion to 2027 gross and adjusted EBITDA margins.
Axogen (NASDAQ: AXGN) announced that its management team will participate in the 24th Annual Morgan Stanley Global Healthcare Conference. According to Axogen, management will be available for one-on-one investor meetings at the event on Tuesday, September 15, 2026.
Trace Biosciences, a clinical-stage biotech focused on nerve-targeted imaging agents, announced a strategic investment from Axogen (NASDAQ: AXGN) as part of Trace's Series A financing. Axogen is described as a global leader in surgical solutions for peripheral nerve repair.
The proceeds are earmarked to advance Trace's Nerve Trace near-infrared fluorescence imaging technology, which provides real-time visualization of nerves during surgery. Trace's lead candidate, Nerve Trace Dx, received FDA IND clearance in December 2025 and has begun a Phase I trial evaluating safety and feasibility in surgical patients, with the new capital intended to support planned Phase II and III trials toward a potential NDA.
Axogen (NASDAQ: AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% from $56.7 million a year earlier, with gross margin of 72.7% versus 74.2%. The quarter showed a GAAP net loss of $1.5 million ($0.03/share) compared with net income of $0.6 million, while adjusted net income was $7.3 million ($0.12/share) versus $5.7 million. Adjusted EBITDA was $8.4 million, down from $9.3 million. Cash, restricted cash, and investments rose to $113.4 million at June 30, 2026, from $103.6 million at March 31, 2026. For 2026, Axogen now expects at least 24% revenue growth, or at least $279 million, gross margin of at least 73%, and positive full-year free cash flow. The company also highlighted broad-based growth across key clinical markets, new Level 1 evidence for Axoguard Nerve Cap, initiation of the Nerve-RESTORE study, and a minority stake in Trace Biosciences.
Axogen (Nasdaq: AXGN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. Phone access is via (877) 407-0993 or (201) 689-8795, with webcast and replay on the Axogen Investors webpage.
Axogen (NASDAQ: AXGN) will participate in the 2026 Bank of America Global Healthcare Conference and present on Wednesday, May 13, 2026 at 9:35 AM PT. A live audio webcast will be available via the company’s Investors website at ir.axogeninc.com.
Axogen (NASDAQ: AXGN) reported first-quarter 2026 revenue of $61.5M, up 26.6% year-over-year, gross margin of 75.2%, and a net loss of $19.6M (or $0.38 per share). Adjusted net income was $4.1M and adjusted EBITDA was $5.7M. Cash and investments totaled $103.6M on March 31, 2026.
The company raised full-year revenue guidance to at least 20% growth or $270M, expects gross margin of 74–76%, and plans to be free cash flow positive for 2026. Axogen completed an upsized offering and repaid its Oberland loan.
Axogen (Nasdaq: AXGN) will report first quarter 2026 financial results on April 28, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET after the release.
Investors can join by phone or listen to a live webcast; an archived replay and presentation slides will be available on the company's Investors page at www.axogeninc.com.
Axogen (NASDAQ: AXGN) reported fourth-quarter 2025 revenue of $59.9M (+21.3% YoY) and full-year 2025 revenue of $225.2M (+20.2% YoY). Full-year adjusted EBITDA was $27.9M. FDA approved the BLA for Avance on Dec 3, 2025. Axogen completed a public offering raising $133.3M net and used $69.7M to repay a loan. 2026 guidance: revenue at least 18% growth (~$265.7M), gross margin 74–76%, and expected free cash flow positive for the year.